LAMEA Autoinjectors Market By Type (Disposable autoinjectors and Reusable autoinjectors), By Application (Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications), By End Use (Hospitals & Clinics and Home care settings), By Country, Industry Analysis and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the LAMEA Autoinjectors Market
The Latin America, Middle East and Africa Autoinjectors Market would witness market growth of 18.7% CAGR during the forecast period (2020-2026).
Epinephrine is considered the first line of treatment for allergic reactions or anaphylaxis. Pharmaceutical companies are bringing technologically advanced epinephrine autoinjectors (EAIs) treatment of anaphylaxis. With the advancement in technology including portable devices, innovative designs, autoinjectors with two auto-injectable doses in one device, autoinjectors made with a 0.5- or 0.75-mg dose of epinephrine for larger adults, the autoinjectors are experiencing higher rate of adoptability.
Also, autoinjectors made with a 0.1-mg dose of epinephrine for infants, autoinjectors with enhanced temperature stability and extended shelf life for epinephrine, weather-resistant casing, and devices that can update patients that the dosage was successfully delivered makes the device more user friendly. Factors that are being focused on for improvement of autoinjectors are removal force of safety cap, override force, ejection time, ejection dosage, needle activation force, needle length, dose setting & audible click detection. These technological advancements are anticipated to drive the adoption of autoinjectors significantly in the coming years.
The existing COVID-19 pandemic has brought about the implementation of a new set of protocols that target to decrease patient visits to hospitals and clinics if it is not emergency conditions in order to prevent the spread of the virus. In such a situation, the inclination for home-use autoinjectors has increased among patients who are suffering from allergies and chronic illnesses. This also safeguards susceptible high-risk populations from exposure to the virus while visiting to hospital.
Autoinjectors are being advanced to support improved concentrations and viscosity of drugs to lessen administration frequency, therefore growing adherence to acclaimed drug protocols. These factors facilitate an opportunity for the growth of the market of autoinjectors in the present COVID-19 scenario.
Based on Type, the market is segmented into Disposable autoinjectors and Reusable autoinjectors. Based on Application, the market is segmented into Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications. Based on End Use, the market is segmented into Hospitals & Clinics and Home care settings. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, GlaxoSmithKline PLC (GSK), Merck Group, Sanofi S.A., Becton, Dickinson and Company, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., Ypsomed AG, AbbVie, Inc. and Biogen, Inc.
Scope of the Study
Market Segments Covered in the Report:
- Disposable autoinjectors
- Reusable autoinjectors
- Rheumatoid Arthritis
- Multiple Sclerosis
- Other Applications
By End Use
- Hospitals & Clinics
- Home care settings
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Eli Lilly and Company
- GlaxoSmithKline PLC (GSK)
- Merck Group
- Sanofi S.A.
- Becton, Dickinson and Company
- Teva Pharmaceuticals Industries Ltd.
- Amgen, Inc.
- Ypsomed AG
- AbbVie, Inc.
- Biogen, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free